PT1113015E - Compostos 3-((2-piperazinilfenil)metil)-1-(4-(trifluorometil)fenil)-2-pirrolidinona opticamente activos, como antagonistas selectivos dos receptores de 5-ht1d - Google Patents
Compostos 3-((2-piperazinilfenil)metil)-1-(4-(trifluorometil)fenil)-2-pirrolidinona opticamente activos, como antagonistas selectivos dos receptores de 5-ht1dInfo
- Publication number
- PT1113015E PT1113015E PT00311130T PT00311130T PT1113015E PT 1113015 E PT1113015 E PT 1113015E PT 00311130 T PT00311130 T PT 00311130T PT 00311130 T PT00311130 T PT 00311130T PT 1113015 E PT1113015 E PT 1113015E
- Authority
- PT
- Portugal
- Prior art keywords
- piperazinylphenyl
- trifluoromethyl
- optically active
- phenyl
- methyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Nutrition Science (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17343799P | 1999-12-29 | 1999-12-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT1113015E true PT1113015E (pt) | 2004-12-31 |
Family
ID=22632024
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT00311130T PT1113015E (pt) | 1999-12-29 | 2000-12-13 | Compostos 3-((2-piperazinilfenil)metil)-1-(4-(trifluorometil)fenil)-2-pirrolidinona opticamente activos, como antagonistas selectivos dos receptores de 5-ht1d |
Country Status (9)
Country | Link |
---|---|
US (2) | US20010039280A1 (pt) |
EP (1) | EP1113015B1 (pt) |
JP (1) | JP3495708B2 (pt) |
AT (1) | ATE276249T1 (pt) |
CA (1) | CA2329576A1 (pt) |
DE (1) | DE60013751T2 (pt) |
DK (1) | DK1113015T3 (pt) |
ES (1) | ES2225031T3 (pt) |
PT (1) | PT1113015E (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005529117A (ja) * | 2002-04-19 | 2005-09-29 | グラクソ グループ リミテッド | 5HT2c受容体に対する親和性を有する化合物及びその治療における使用 |
JP2007537151A (ja) * | 2004-01-29 | 2007-12-20 | ファイザー・プロダクツ・インク | γ−アミノ酪酸モジュレータと5−HT1B受容体アンタゴニストとの組合せ |
ES2371927T3 (es) | 2005-01-13 | 2012-01-11 | Ge Healthcare Limited | Compuestos de bencil-lactama marcados con 11c y su uso como agentes de obtención de imágenes. |
US20090264650A1 (en) * | 2005-03-31 | 2009-10-22 | Nobuo Cho | Prophylactic/Therapeutic Agent for Diabetes |
WO2007012964A1 (en) * | 2005-07-25 | 2007-02-01 | Pfizer Products Inc. | Preparation of alkylpiperazinylphenyl compounds by classical resolution |
WO2007026224A2 (en) * | 2005-08-31 | 2007-03-08 | Pfizer Products Inc. | 5-ht1b antagonist composition for depression, anxiety and cognition |
WO2014078568A1 (en) | 2012-11-14 | 2014-05-22 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
WO2020183011A1 (en) | 2019-03-14 | 2020-09-17 | Institut Curie | Htr1d inhibitors and uses thereof in the treatment of cancer |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2083698C (en) * | 1990-06-01 | 1997-11-04 | Albert A. Carr | (+)-alpha-(2,3-dimethoxyphenyl)-1- [2-(4-fluorophenyl) ethyl]-4-piperidinemethanol |
FR2670491B1 (fr) * | 1990-12-14 | 1993-02-05 | Adir | Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les renfermant. |
FR2692264B1 (fr) * | 1992-06-12 | 1994-08-05 | Adir | Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les contenant. |
US6462048B2 (en) * | 1996-03-29 | 2002-10-08 | Pfizer Inc. | Benzyl(idene)-lactam derivatives, their preparation and their use as selective (ant)agonists of 5-HT1A- and/or 5-HT1D receptors |
-
2000
- 2000-12-13 EP EP00311130A patent/EP1113015B1/en not_active Expired - Lifetime
- 2000-12-13 DK DK00311130T patent/DK1113015T3/da active
- 2000-12-13 DE DE60013751T patent/DE60013751T2/de not_active Expired - Fee Related
- 2000-12-13 AT AT00311130T patent/ATE276249T1/de not_active IP Right Cessation
- 2000-12-13 ES ES00311130T patent/ES2225031T3/es not_active Expired - Lifetime
- 2000-12-13 PT PT00311130T patent/PT1113015E/pt unknown
- 2000-12-19 US US09/740,361 patent/US20010039280A1/en not_active Abandoned
- 2000-12-27 CA CA002329576A patent/CA2329576A1/en not_active Abandoned
-
2001
- 2001-01-04 JP JP2001000227A patent/JP3495708B2/ja not_active Expired - Fee Related
-
2002
- 2002-08-09 US US10/215,910 patent/US20030083337A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
DE60013751D1 (de) | 2004-10-21 |
ES2225031T3 (es) | 2005-03-16 |
JP2001187781A (ja) | 2001-07-10 |
ATE276249T1 (de) | 2004-10-15 |
EP1113015A1 (en) | 2001-07-04 |
DK1113015T3 (da) | 2004-12-13 |
US20030083337A1 (en) | 2003-05-01 |
CA2329576A1 (en) | 2001-06-29 |
JP3495708B2 (ja) | 2004-02-09 |
DE60013751T2 (de) | 2005-09-29 |
US20010039280A1 (en) | 2001-11-08 |
EP1113015A4 (en) | 2001-03-23 |
EP1113015B1 (en) | 2004-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EE200300403A (et) | N-asendatud mittearomaatne heterotsükliline ühend, seda sisaldav ravimkompositsioon ning ühendi kasutamine ravimina | |
JP2008110984A5 (pt) | ||
ATE269846T1 (de) | N-substituierte aminotetraline als neuropeptid y y5 rezeptor-liganden und ihre anwendung zur behandlung von fettleibigkeit und anderen erkrankungen | |
EA200701324A1 (ru) | Соединения пиридина для лечения заболеваний, опосредованных действием простагландина | |
BR0112756A (pt) | Composto, composição farmacêutica, métodos para o tratamento de doenças mediadas por prostaglandina, de congestão nasal, asma alérgica, e rinite alérgica, e, uso de um composto | |
DE69922676D1 (de) | N-aralkylaminotetraline als neuropeptid-y-y5-rezeptorliganden | |
WO2005092307A3 (en) | Pharmaceutical dosage forms and compositions of 5-ht1a receptor antagonists | |
ATE303369T1 (de) | Glucocorticoid rezeptor modulatoren | |
RU2007120454A (ru) | Производные хинуклидина и их применение в качестве антагонистов мускариновых рецепторов м3 | |
UA93209C2 (ru) | Комбинация снотворного агента продолжительного действия эпливансерина и снотворного агента короткого действия золпидема | |
EA200601378A1 (ru) | Гидроизоиндолиновые антагонисты рецептора тахикинина | |
CA2252898A1 (en) | Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2(1h)-indol-2-one(=ziprasidone), its preparation and its use as dopamine d2 antagonist | |
ATE327974T1 (de) | Modulatoren des glucocorticoid-rezeptors | |
SG164283A1 (en) | New benzimidazole derivatives | |
YU53100A (sh) | Derivati 2-ariletil-(piperidin-4-ilmetil)amina kao antagonisti muskarinskih receptora | |
PT1113015E (pt) | Compostos 3-((2-piperazinilfenil)metil)-1-(4-(trifluorometil)fenil)-2-pirrolidinona opticamente activos, como antagonistas selectivos dos receptores de 5-ht1d | |
MA26541A1 (fr) | Nouvelles imidazolines, procede pour les preparer, compositions pharmaceutiques les contenant et leur utilisation dans le traitement de maladies soulagees par un traitement avec un antagoniste des recepteurs des prostaglandines | |
TW200519101A (en) | Benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors | |
ATE434437T1 (de) | Verwendung von antagonisten der 5-ht3-rezeptoren zur behandlung von muskuloeskeletalen erkrankungen | |
CL2008003066A1 (es) | Compuestos derivados de 1-[3-(fenilamino)-5-(piridin-4-il)-1h-1,2,4-triazol-1-il]-alquil-2-ol; composición farmacéutica; procedimiento de preparación de dicha composición; y uso para el tratamiento o prevención de una enfermedad del sistema nervioso central. | |
ATE362364T1 (de) | Substituierte azabicyclo hexane derivate als muscarin rezeptor antagonisten | |
TW200519102A (en) | Hydronopol substituted benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors | |
RU2003115431A (ru) | Новые применения объединенных агонистов 5-нт1а и ингибиторов обратного захвата серотонина | |
SE9900190D0 (sv) | New compounds | |
WO2007030589A3 (en) | Pharmaceutical dosage forms and compositions comprising lecoztan |